Neural Regeneration Research ›› 2015, Vol. 10 ›› Issue (10): 1591-1593.doi: 10.4103/1673-5374.167751

Previous Articles     Next Articles

Repositioning imatinib for spinal cord injury

Jacob Kjell*, †, Lars Olson   

  1. Department of Neuroscience, Karolinska Institutet, Stockholm,
    Sweden
  • Received:2015-09-17 Online:2015-10-28 Published:2015-10-28
  • Contact: Jacob Kjell, Ph.D., jacob.kjell@ki.se, jacob.kjell@med.uni-muenchen.de.
  • Supported by:

    Work discussed herein was supported by grants from the Swedish Brain Foundation, the Swedish Research Council (K2012-62X-03185-42-4; to LO), Swedish Foundation for Strategic Research, Wings for Life, SSMF, the Swedish Agency for Innovation Systems (VINNOVA), an ERC Advanced Investigator grant (322744; to LO), the StratNeuro initiative, Karolinska Institutet Research Foundations and the Karolinska Institutet DPA program.

PDF

598

Abstract:

There are currently a number of drugs in clinical trial or close to it, several of them repositioned. In imatinib we believe we have found an additional promising therapeutic candidate, together with candidate efficacy biomarkers. Previous trials have proved the challenge is daunting. Nevertheless, taking all current approaches into account, there is now room for cautious optimism that there will be drugs available in the not too distant future, able to dampen the lasting effects of acute spinal cord damage.